Abstract:Diabetes, Obesity and MetabolismEarly View RESEARCH LETTER Effectiveness and safety of once-weekly subcutaneous semaglutide versus other glucose-lowering agents in real-world patients with type 2 diabetes: A retrospective, observational post-marketing study Chenyang Shi PharmD, Chenyang Shi PharmD orcid.org/0000-0002-0626-0781 Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiaotong University, Shanghai, ChinaSearch for more papers by this authorYijiong Tan MPharm, Yijiong Tan MPharm Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiaotong University, Shanghai, ChinaSearch for more papers by this authorShanshan Hu MPharm, Shanshan Hu MPharm Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiaotong University, Shanghai, ChinaSearch for more papers by this authorYingyi Qin PharmD, Yingyi Qin PharmD Department of Military Health Statistics, Naval Medical University, Shanghai, ChinaSearch for more papers by this authorYuanjun Tang MPharm, Yuanjun Tang MPharm Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiaotong University, Shanghai, ChinaSearch for more papers by this authorYufan Wang PharmD, Yufan Wang PharmD Department of Endocrinology and Metabolism, Shanghai General Hospital, Shanghai Jiaotong University, Shanghai, ChinaSearch for more papers by this authorGuorong Fan PharmD, Corresponding Author Guorong Fan PharmD guorfan@163.com Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiaotong University, Shanghai, China Correspondence Guorong Fan, Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiaotong University, Shanghai, 210008, China. Email: guorfan@163.comSearch for more papers by this author Chenyang Shi PharmD, Chenyang Shi PharmD orcid.org/0000-0002-0626-0781 Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiaotong University, Shanghai, ChinaSearch for more papers by this authorYijiong Tan MPharm, Yijiong Tan MPharm Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiaotong University, Shanghai, ChinaSearch for more papers by this authorShanshan Hu MPharm, Shanshan Hu MPharm Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiaotong University, Shanghai, ChinaSearch for more papers by this authorYingyi Qin PharmD, Yingyi Qin PharmD Department of Military Health Statistics, Naval Medical University, Shanghai, ChinaSearch for more papers by this authorYuanjun Tang MPharm, Yuanjun Tang MPharm Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiaotong University, Shanghai, ChinaSearch for more papers by this authorYufan Wang PharmD, Yufan Wang PharmD Department of Endocrinology and Metabolism, Shanghai General Hospital, Shanghai Jiaotong University, Shanghai, ChinaSearch for more papers by this authorGuorong Fan PharmD, Corresponding Author Guorong Fan PharmD guorfan@163.com Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiaotong University, Shanghai, China Correspondence Guorong Fan, Department of Clinical Pharmacy, Shanghai General Hospital, Shanghai Jiaotong University, Shanghai, 210008, China. Email: guorfan@163.comSearch for more papers by this author First published: 18 March 2024 https://doi.org/10.1111/dom.15552 Chenyang Shi, Yijiong Tan and Shanshan Hu contributed equally to this work. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat CONFLICT OF INTEREST STATEMENT The authors declare no potential conflicts of interest. Open Research PEER REVIEW The peer review history for this article is available at https://www.webofscience.com/api/gateway/wos/peer-review/10.1111/dom.15552. DATA AVAILABILITY STATEMENT The raw data supporting the conclusions of this article will be made available by the authors. Further inquiries can be directed to the corresponding author. Supporting Information Filename Description dom15552-sup-0001-supinfo.docxWord 2007 document , 39.6 KB Data S1. Supporting Information. dom15552-sup-0002-FigureS1.zipZip archive, 278.8 KB Figure S1. Changes in total cholesterol and uric acid when treatment with semaglutide compared to non-GLP-1RA from baseline to continuous clinical endpoints over time (T3 to T12). (A) Changes in total cholesterol. (B) Changes in uric acid. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article. REFERENCES 1Quan J, Zhao Z, Wang L, et al. Potential health and economic impact associated with achieving risk factor control in Chinese adults with diabetes: a microsimulation modelling study. Lancet Reg Health West Pac. 2023; 14(33):100690. doi:10.1016/j.lanwpc.2023.100690 10.1016/j.lanwpc.2023.100690 Google Scholar 2Pandey S, Mangmool S, Parichatikanond W. Multifaceted roles of GLP-1 and its analogs: a review on molecular mechanisms with a cardiotherapeutic perspective. Pharmaceuticals. 2023; 16(6): 836. doi:10.3390/ph16060836 10.3390/ph16060836 CASWeb of Science®Google Scholar 3Madsbad S, Holst JJ. Cardiovascular effects of incretins: focus on glucagon-like peptide-1 receptor agonists. Cardiovasc Res. 2023; 119(4): 886-904. doi:10.1093/cvr/cvac112 10.1093/cvr/cvac112 CASPubMedWeb of Science®Google Scholar 4Ji L, Dong X, Li Y, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: a 30-week, double-blind, phase 3a, randomized trial. Diabetes Obes Metab. 2021; 23(2): 404-414. doi:10.1111/dom.14232 10.1111/dom.14232 CASPubMedWeb of Science®Google Scholar 5Aroda VR, Ahmann A, Cariou B, et al. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: insights from the SUSTAIN 1-7 trials. Diabetes Metab. 2019; 45(5): 409-418. doi:10.1016/j.diabet 10.1016/j.diabet.2018.12.001 CASPubMedWeb of Science®Google Scholar 6Yale JF, Bodholdt U, Catarig AM, et al. Real-world use of once-weekly semaglutide in patients with type 2 diabetes: pooled analysis of data from four SURE studies by baseline characteristic subgroups. BMJ Open Diabetes Res Care. 2022; 10(2):e002619. doi:10.1136/bmjdrc-2021-002619 10.1136/bmjdrc-2021-002619 PubMedWeb of Science®Google Scholar 7Aroda VR, Faurby M, Lophaven S, Noone J, Wolden ML, Lingvay I. Insights into the early use of oral semaglutide in routine clinical practice: the IGNITE study. Diabetes Obes Metab. 2021; 23(9): 2177-2182. doi:10.1111/dom.14453 10.1111/dom.14453 CASPubMedWeb of Science®Google Scholar 8 World Medical Association. World medical association declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013; 310: 2191-2194. doi:10.1001/JAMA.2013.281053 10.1001/jama.2013.281053 CASPubMedWeb of Science®Google Scholar 9Rudofsky G, Catarig AM, Favre L, et al. Real-world use of once-weekly semaglutide in patients with type 2 diabetes: results from the SURE Switzerland multicentre, prospective, observational study. Diabetes Res Clin Pract. 2021; 178:108931. doi:10.1016/j.diabres.2021.108931 10.1016/j.diabres.2021.108931 CASPubMedWeb of Science®Google Scholar 10Mohammedi K, Belhatem N, Berentzen TL, Catarig AM, Potier L. Once-weekly semaglutide use in patients with type 2 diabetes: results from the SURE France multicentre, prospective, observational study. Diabetes Obes Metab. 2023; 25(7): 1855-1864. doi:10.1111/dom.15045 10.1111/dom.15045 CASPubMedWeb of Science®Google Scholar 11Vilsbøll T, Lindahl CØ, Nielsen NF, Tikkanen CK. Real-world impact of once-weekly subcutaneous semaglutide after 2 years of follow-up: results from a nationwide observational study in people with type 2 diabetes. Diabetes Obes Metab. 2023; 25(6): 1740-1749. doi:10.1111/dom.15031 10.1111/dom.15031 PubMedWeb of Science®Google Scholar 12Garcia de Lucas MD, Miramontes-González JP, Avilés-Bueno B, Jiménez-Millán AI, Rivas-Ruiz F, Pérez-Belmonte LM. Real-world use of once-weekly semaglutide in patients with type 2 diabetes at an outpatient clinic in Spain. Front Endocrinol. 2022; 16(13):995646. doi:10.3389/fendo.2022.995646 10.3389/fendo.2022.995646 Google Scholar 13Simental-Mendía M, Linden-Torres E, Sánchez-García A, Sahebkar A, Simental-Mendía LE. Effect of glucagon-like peptide-1 receptor agonists on renal function: a meta-analysis of randomized controlled trials. Br J Clin Pharmacol. 2022; 88(8): 3566-3576. doi:10.1111/bcp.15304 10.1111/bcp.15304 CASPubMedWeb of Science®Google Scholar Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation

Abstract:Diabetes/Metabolism Research and ReviewsVolume 37, Issue 3 e3393 COMMENTARY Tackling obesity during the COVID-19 pandemic Amit Akirov, Amit Akirov orcid.org/0000-0002-9376-344X Institute of Endocrinology, Beilinson Hospital, Petach Tikva, Israel Sackler School of Medicine, Tel Aviv University, Tel Aviv, IsraelSearch for more papers by this authorAvivit Cahn, Corresponding Author Avivit Cahn [email protected] orcid.org/0000-0002-7830-9994 Diabetes Unit, Department of Endocrinology and Metabolism, Faculty of Medicine, Hadassah Hebrew University Medical Center, Jerusalem, Israel Correspondence Avivit Cahn, Diabetes Unit, Endocrinology and Metabolism Unit, Hadassah Hebrew University Hospital, PO Box 12000, Jerusalem 91120, Israel. Email: [email protected]Search for more papers by this authorStefano Del Prato, Stefano Del Prato orcid.org/0000-0002-5388-0270 Department of Clinical & Experimental Medicine, Section of Metabolic Diseases and Diabetes, University of Pisa, Pisa, ItalySearch for more papers by this authorPhilip Home, Philip Home orcid.org/0000-0001-5187-710X Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UKSearch for more papers by this authorLuc Van Gaal, Luc Van Gaal Department of Endocrinology & Metabolism, Antwerp University Hospital, Edegem-Antwerp, BelgiumSearch for more papers by this authorJuliana Chan, Juliana Chan Department of Medicine and Therapeutics, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong, China Hong Kong Institute of Diabetes and Obesity, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong, China Li Ka Shing Institute of Health Science, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong, ChinaSearch for more papers by this authorGuang Ning, Guang Ning Key Laboratory for Endocrine and Metabolic Diseases of Ministry of Health, Department of Endocrine and Metabolic Diseases, Rui-Jin Hospital, Shanghai Jiao-Tong University School of Medicine, Shanghai, ChinaSearch for more papers by this authorItamar Raz, Itamar Raz orcid.org/0000-0003-0209-4453 Diabetes Unit, Department of Endocrinology and Metabolism, Faculty of Medicine, Hadassah Hebrew University Medical Center, Jerusalem, IsraelSearch for more papers by this author on behalf of the Global CODHY Expert Forum Amit Akirov, Amit Akirov orcid.org/0000-0002-9376-344X Institute of Endocrinology, Beilinson Hospital, Petach Tikva, Israel Sackler School of Medicine, Tel Aviv University, Tel Aviv, IsraelSearch for more papers by this authorAvivit Cahn, Corresponding Author Avivit Cahn [email protected] orcid.org/0000-0002-7830-9994 Diabetes Unit, Department of Endocrinology and Metabolism, Faculty of Medicine, Hadassah Hebrew University Medical Center, Jerusalem, Israel Correspondence Avivit Cahn, Diabetes Unit, Endocrinology and Metabolism Unit, Hadassah Hebrew University Hospital, PO Box 12000, Jerusalem 91120, Israel. Email: [email protected]Search for more papers by this authorStefano Del Prato, Stefano Del Prato orcid.org/0000-0002-5388-0270 Department of Clinical & Experimental Medicine, Section of Metabolic Diseases and Diabetes, University of Pisa, Pisa, ItalySearch for more papers by this authorPhilip Home, Philip Home orcid.org/0000-0001-5187-710X Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UKSearch for more papers by this authorLuc Van Gaal, Luc Van Gaal Department of Endocrinology & Metabolism, Antwerp University Hospital, Edegem-Antwerp, BelgiumSearch for more papers by this authorJuliana Chan, Juliana Chan Department of Medicine and Therapeutics, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong, China Hong Kong Institute of Diabetes and Obesity, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong, China Li Ka Shing Institute of Health Science, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong, ChinaSearch for more papers by this authorGuang Ning, Guang Ning Key Laboratory for Endocrine and Metabolic Diseases of Ministry of Health, Department of Endocrine and Metabolic Diseases, Rui-Jin Hospital, Shanghai Jiao-Tong University School of Medicine, Shanghai, ChinaSearch for more papers by this authorItamar Raz, Itamar Raz orcid.org/0000-0003-0209-4453 Diabetes Unit, Department of Endocrinology and Metabolism, Faculty of Medicine, Hadassah Hebrew University Medical Center, Jerusalem, IsraelSearch for more papers by this author on behalf of the Global CODHY Expert Forum First published: 14 August 2020 https://doi.org/10.1002/dmrr.3393Citations: 2 Amit Akirov and Avivit Cahn contributed equally to this paper. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat CONFLICT OF INTEREST All authors have no conflict of interest relevant to this paper to declare. ETHICAL STATEMENT This is a review and not a study involving human or animal studies, therefore ethics approval was not required. AUTHOR CONTRIBUTION Amit Akirov and Avivit Cahn drafted the manuscript. All authors reviewed the manuscript, provided comments and expanded discussion and all authors approve the final submitted version. REFERENCES 1Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China. JAMA. 2020; 323(13): 1239. http://dx.doi.org/10.1001/jama.2020.2648. 10.1001/jama.2020.2648 CASPubMedWeb of Science®Google Scholar 2Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395: 1054-1062. 10.1016/S0140-6736(20)30566-3 CASPubMedWeb of Science®Google Scholar 3Zhang F, Xiong Y, Wei Y, et al. Obesity predisposes to the risk of higher mortality in young COVID-19 patients. J Med Virol. 2020. http://dx.doi.org/10.1002/jmv.26039. Web of Science®Google Scholar 4Gao F, Zheng KI, Wang X, et al. Obesity is a risk factor for greater COVID-19 severity. Diabetes Care. 2020; 43: e72-e74. 10.2337/dc20-0682 CASPubMedWeb of Science®Google Scholar 5Caussy C, Pattou F, Wallet F, et al. Prevalence of obesity among adult inpatients with COVID-19 in France. Lancet Diabetes Endocrinol. 2020; 8: 562-564. 10.1016/S2213-8587(20)30160-1 CASPubMedWeb of Science®Google Scholar 6Busetto L, Bettini S, Fabris R, et al. Obesity and COVID-19: an Italian snapshot. Obesity. 2020. http://dx.doi.org/10.1002/oby.22918. 10.1002/oby.22918 PubMedWeb of Science®Google Scholar 7Tamara A, Tahapary DL. Obesity as a predictor for a poor prognosis of COVID-19: a systematic review. Diabetes Metab Syndr Clin Res Rev. 2020; 14: 655-659. 10.1016/j.dsx.2020.05.020 PubMedWeb of Science®Google Scholar 8Hajifathalian K, Kumar S, Newberry C, et al. Obesity is associated with worse outcomes in COVID-19: analysis of early data from New York city. Obesity. 2020. http://dx.doi.org/10.1002/oby.22923. 10.1002/oby.22923 PubMedWeb of Science®Google Scholar 9Simonnet A, Chetboun M, Possy J, et al. High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV- 2) requiring invasive mechanical ventilation. Obesity (Silver Spring). 2020; 28: 1195-1199. 10.1002/oby.22831 CASPubMedWeb of Science®Google Scholar 10Drucker DJ. Coronavirus infections and type 2 diabetes-shared pathways with therapeutic implications. Endocr Rev. 2020; 41: bnaa011. 10.1210/endrev/bnaa011 PubMedWeb of Science®Google Scholar 11Hales K, Carroll M, Fryar C, Ogden C. Prevalence of obesity and severe obesity among adults: United States, 2017–2018. NCHS Data Brief. 2020;(360): 1-8. Google Scholar 12Rundle AG, Park Y, Herbstman JB, Kinsey EW, Wang YC. COVID-19–related school closings and risk of weight gain among children. Obesity. 2020; 28: 1008-1009. 10.1002/oby.22813 CASPubMedWeb of Science®Google Scholar 13Pellegrini M, Ponzo V, Rosato R, et al. Changes in weight and nutritional habits in adults with obesity during the "lockdown" period caused by the COVID-19 virus emergency. Nutrients. 2020; 12: 2016. 10.3390/nu12072016 CASPubMedWeb of Science®Google Scholar 14Ghosh A, Arora B, Gupta R, Anoop S, Misra A. Effects of nationwide lockdown during COVID-19 epidemic on lifestyle and other medical issues of patients with type 2 diabetes in north India. Diabetes Metab Syndr. 2020; 14; 917-920. 10.1016/j.dsx.2020.05.044 PubMedWeb of Science®Google Scholar 15He M, Xian Y, Lv X, He J, Ren Y. Changes in body weight, physical activity and lifestyle during the semi-lockdown period after the outbreak of COVID-19 in China: an online survey. Disaster Med Public Health Prep. 2020; 1-6. http://dx.doi.org/10.1017/dmp.2020.237. 10.1017/dmp.2020.237 Google Scholar 16Yates T, Razieh C. Obesity and risk of COVID-19: analysis of UK Biobank. Prim Care Diabetes. 2020, S1751-S991830196–0. 10.1016/j.pcd.2020.05.011 PubMedWeb of Science®Google Scholar 17Lighter J, Phillips M, Hochman S, et al. Obesity in patients younger than 60 years is a risk factor for COVID-19 hospital admission. Clin Infect Dis. 2020; 71(15): 896-897. http://dx.doi.org/10.1093/cid/ciaa415. 10.1093/cid/ciaa415 CASPubMedWeb of Science®Google Scholar 18Kass DA, Duggal P, Cingolani O. Obesity could shift severe COVID-19 disease to younger ages. Lancet. 2020; 395: 1544-1545. 10.1016/S0140-6736(20)31024-2 CASPubMedWeb of Science®Google Scholar 19Cariou B, Hadjadj S, Wargny M, et al. Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. Diabetologia. 2020; 63(8): 1500-1515. http://dx.doi.org/10.1007/s00125-020-05180-x. 10.1007/s00125-020-05180-x CASPubMedWeb of Science®Google Scholar 20Holman N, Knighton P, Kar P, et al. Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. Lancet Diabetes Endocrinol. 2020. http://dx.doi.org/10.1016/s2213-8587(20)30271-0. 10.1016/S2213-8587(20)30271-0 Web of Science®Google Scholar 21 OpenSAFELY Collaborative, Williamson E, Walker AJ, et al. OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients. medRxiv. 2020. Google Scholar 22Klok F, Kruip M, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020; 191: 145-147. 10.1016/j.thromres.2020.04.013 CASPubMedWeb of Science®Google Scholar 23Poyiadji N, Cormier P, Patel PY, et al. Acute pulmonary embolism and COVID-19. Radiology. 2020: 201955. http://dx.doi.org/10.1148/radiol.2020201955. 10.1148/radiol.2020201955 PubMedWeb of Science®Google Scholar 24Tibiriçá E, De Lorenzo A. Increased severity of COVID-19 in people with obesity: are we overlooking plausible biological mechanisms? Obesity. 2020; 28(8): 1374. http://dx.doi.org/10.1002/oby.22887. 10.1002/oby.22887 CASPubMedWeb of Science®Google Scholar 25Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020; 395: 1417–1418. 10.1016/S0140-6736(20)30937-5 CASPubMedWeb of Science®Google Scholar 26Kassir R. Risk of COVID-19 for patients with obesity. Obes Rev. 2020: 21: e13034. 10.1111/obr.13034 CASPubMedWeb of Science®Google Scholar 27Watanabe M, Risi R, Tuccinardi D, Baquero CJ, Manfrini S, Gnessi L. Obesity and SARS-CoV-2: a population to safeguard. Diabetes Metab Res Rev. 2020. http://dx.doi.org/10.1002/dmrr.3325. 10.1002/dmrr.3325 PubMedWeb of Science®Google Scholar 28Watanabe M, Caruso D, Tuccinardi D, et al. Visceral fat shows the strongest association with the need of intensive care in patients with COVID-19. Metabolism. 2020; 154319. http://dx.doi.org/10.1016/j.metabol.2020.154319. 10.1016/j.metabol.2020.154319 PubMedWeb of Science®Google Scholar 29Kruglikov IL, & Scherer PE. The role of adipocytes and adipocyte-like cells in the severity of COVID-19 infections. Obesity. 2020; 28: 1187–1190. 10.1002/oby.22856 CASPubMedWeb of Science®Google Scholar 30Teymoori-Rad M, Shokri F, Salimi V, Marashi SM. The interplay between vitamin D and viral infections. Rev Med Virol. 2019; 29: e2032. 10.1002/rmv.2032 PubMedWeb of Science®Google Scholar 31Mohamed-Hussein AAR, Aly KME, Ibrahim MEAA. Should aspirin be used for prophylaxis of COVID-19-induced coagulopathy? Med Hypotheses. 2020; 144: 109975. 10.1016/j.mehy.2020.109975 CASPubMedWeb of Science®Google Scholar 32Ayerbe L, Risco C, Ayis S. The association between treatment with heparin and survival in patients with COVID-19. J Thromb Thrombolysis. 2020; 50(2): 298-301. http://dx.doi.org/10.1007/s11239-020-02162-z. 10.1007/s11239-020-02162-z CASPubMedWeb of Science®Google Scholar 33Martineau AR, Jolliffe DA, Hooper RL, et al. Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data. BMJ. 2017; 356: i6583. 10.1136/bmj.i6583 PubMedWeb of Science®Google Scholar 34Zhu L, She Z-G, Cheng X, et al. Association of blood glucose control and outcomes in patients with COVID-19 and pre-existing type 2 diabetes. Cell Metab. 2020; 31: 30238–30242. 10.1016/j.cmet.2020.04.021 Web of Science®Google Scholar 35Wang Z, Du Z, Zhu F. Glycosylated hemoglobin is associated with systemic inflammation, hypercoagulability, and prognosis of COVID-19 patients. Diabetes Res Clin Pract. 2020; 164: 108214. http://dx.doi.org/10.1016/j.diabres.2020.108214. 10.1016/j.diabres.2020.108214 CASPubMedWeb of Science®Google Scholar 36Gao C, Cai Y, Zhang K, et al. Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study. Eur Heart J. 2020; 41: 2058–2066. 10.1093/eurheartj/ehaa433 CASPubMedWeb of Science®Google Scholar 37Woo Baidal JA, Chang J, Hulse E, Turetsky R, Parkinson K, Rausch JC. Zooming toward a telehealth solution for vulnerable children with obesity during coronavirus 2019. Obesity. 2020; 28(7): 1184-1186. http://dx.doi.org/10.1002/oby.22860. 10.1002/oby.22860 CASPubMedWeb of Science®Google Scholar Citing Literature Volume37, Issue3March 2021e3393 This article also appears in:COVID-19 and Diabetes ReferencesRelatedInformation

Safety Concerns of Sodium-Glucose Co-Transporter-2 Inhibitors in Type 1 Diabetes: A Real-World Study from the Perspective of the Food and Drug Administration Adverse Event Reporting System

Letter by Deng Et Al Regarding Article, "risk of Macrovascular and Microvascular Disease in Diabetes Diagnosed Using Oral Glucose Tolerance Test with and Without Confirmation by Hemoglobin A1c: the Whitehall II Cohort Study".

Effectiveness and Safety of Once-Weekly Subcutaneous Semaglutide Versus Other Glucose-Lowering Agents in Real-World Patients with Type 2 Diabetes: A Retrospective, Observational Post-Marketing Study.

Cardiovascular Safety of Sulphonylurea: Comment on the Study by Monami Et Al.

The Safety and Efficacy of Sodium Glucose Co-transporter 2 Inhibitors Combined with Insulin in Adults with Type 1 Diabetes: A Meta-analysis of Randomized Controlled Trials.

1121-P: Effectiveness of Sodium–Glucose Cotransporter 2 Inhibitors on Coronary Heart Disease Compared with Other Glucose Lowering Drugs

First-line treatment with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists in type 2 diabetic population at low risk of cardiovascular disease: a meta-analysis

International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium–Glucose Cotransporter (SGLT) Inhibitors

Real-World Safety of the Combined Use of Dapagliflozin and Metformin in Type 2 Diabetes Mellitus Patients in China-Post Hoc Analysis of the DONATE Study

Sodium-glucose Co-Transporter-2 Inhibitors in Patients with Chronic Kidney Disease with or Without Type 2 Diabetes: Systematic Review and Meta-Analysis

Sodium-glucose cotransporter-2 inhibitors and abnormal serum potassium: a real-world, pharmacovigilance study

Longer-term Benefits and Risks of Sodium-Glucose Cotransporter-2 Inhibitors in Type 2 Diabetes: a Systematic Review and Meta-analysis

Comparison over Time of Adverse Drug Reactions in Diabetes Patients Treated with Sodium-Glucose Cotransporter 2 Inhibitors

Tackling Obesity During the COVID‐19 Pandemic

Natural Language Processing Extracted Social And Behavioral Determinants Of Health And Newer Glucose-lowering Drug Initiation Among Real-world Patients With Type 2 Diabetes

The Risk Factors of Diabetic Ketosis and Diabetic Ketoacidosis among Patients with Type 2 Diabetes Mellitus Treated with SGLT2 Inhibitors: a Retrospective Study.

Sodium-Glucose Co-transporter-2 Inhibitors in Type 1 Diabetes Mellitus: The Framework for Recommendations for Their Potential Use

Letter by Jin-Shan and Xue-Bin Regarding Article, "cardiac Outcomes after Ischemic Stroke or Transient Ischemic Attack: Effects of Pioglitazone in Patients with Insulin Resistance Without Diabetes Mellitus".

931-P: Real-World Study on the Effect of SGLT2 Inhibitors in Patients with Type 2 Diabetes in China

1230-P: Low Real-World Use of SGLT2 Inhibitors in People with Diabetes and Heart Failure—A Population Cohort Study

Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials